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Abstract
Human muscle-derived progenitor cells (hMDPCs) offer great promise for muscle cell-based regenerative medicine;
however, prolonged ex-vivo expansion using animal sera is necessary to acquire sufficient cells for transplantation. Due to
the risks associated with the use of animal sera, the development of a strategy for the ex vivo expansion of hMDPCs is
required. The purpose of this study was to investigate the efficacy of using platelet-rich plasma (PRP) for the ex-vivo
expansion of hMDPCs. Pre-plated MDPCs, myoendothelial cells, and pericytes are three populations of hMDPCs that we
isolated by the modified pre-plate technique and Fluorescence Activated Cell Sorting (FACS), respectively. Pooled allogeneic
human PRP was obtained from a local blood bank, and the effect that thrombin-activated PRP-releasate supplemented
media had on the ex-vivo expansion of the hMDPCs was tested against FBS supplemented media, both in vitro and in vivo.
PRP significantly enhanced short and long-term cell proliferation, with or without FBS supplementation. Antibody-
neutralization of PDGF significantly blocked the mitogenic/proliferative effects that PRP had on the hMDPCs. A more stable
and sustained expression of markers associated with stemness, and a decreased expression of lineage specific markers was
observed in the PRP-expanded cells when compared with the FBS-expanded cells. The in vitro osteogenic, chondrogenic,
and myogenic differentiation capacities of the hMDPCs were not altered when expanded in media supplemented with PRP.
All populations of hMDPCs that were expanded in PRP supplemented media retained their ability to regenerate myofibers
in vivo. Our data demonstrated that PRP promoted the proliferation and maintained the multi-differentiation capacities of
the hMDPCs during ex-vivo expansion by maintaining the cells in an undifferentiated state. Moreover, PDGF appears to be a
key contributing factor to the beneficial effect that PRP has on the proliferation of hMDPCs.
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Introduction
Skeletal muscle is a good source of various cellular progenitors
with potential musculoskeletal therapeutic applications [1,2,3]. A
population of cells has been isolated by a modified pre-plate
technique from mouse skeletal muscle, that when compared to
myoblasts, display a superior regeneration capacity in various
musculoskeletal tissues, including skeletal and cardiac muscles,
bone, and articular cartilage [4,5,6,7]. When compared to
myoblasts, these cells, termed muscle-derived stem cells (MDSCs)
[8], demonstrated the capacity for self-renewal, long term
proliferation, multi-potent differentiation, and a superior ability
to survive, due to their increased resistance to oxidative and
inflammatory stresses [9]. Several populations of human muscle-
derived progenitor cells, including satellite cells [10,11], myo-
endothelial cells [12], and pericytes [2,3,13,14,15,16] have also
been isolated using the pre-plate technique and Fluorescence
Activated Cell Sorting (FACS), respectively [12,16]. These muscle-
derived cells are multi-potent progenitor cells that exhibit similar
multi-lineage differentiation potentials and can differentiate into
muscle, bone, cartilage, and fat both in vitro and in vivo [12,16]. In
the current study we refer to these different populations of cells
collectively as human muscle-derived progenitor cells (hMDPCs).
hMDPCs offer great promise for muscle cell-based regenerative
medicine; however, due to their relative scarcity (MDSCs: 0.05%–
0.1%; Myoendothelial cells: 0.460.1% [12]; Pericytes:
0.2960.09% [16]), prolonged ex-vivo expansion is necessary to
acquire sufficient cell numbers for therapeutic transplantation.
This involves exposing the stem cells to commercial animal sera
such as fetal bovine serum (FBS) or fetal calf serum (FCS), and/or
to growth factors and other supplements such as chicken embryo
extract (CEE). Due to the risks associated with the use of these
animal sera [17,18], the development of an appropriate strategy
for hMDPCs ex-vivo expansion is required.
Platelet-rich plasma (PRP) can be rapidly and easily obtained by
centrifugal separation from whole blood. Multiple growth factors
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are concentrated in PRP at high levels after centrifugation, hence,
PRP obtained from patients can be used as an autologous source
of growth factors for various tissue repairs [19,20,21,22,23]. The
introduction of PRP into clinical practice was originally suggested
by Marx et al. [24] in 1998. In addition to being autologous in
nature, and therefore posing no risk of disease transmission or
immunogenic reaction, PRP offers the advantage of being a
growth factor concentrate containing the ‘‘right’’ factors at the
‘‘right’’ proportions necessary for aiding the healing process of
various tissues. Despite the expanding potentials of directly using
PRP for accelerating the healing of a variety of tissues, there is also
a rising interest in combining PRP with mesenchymal stem cells
(MSCs) for tissue regeneration applications. PRP is a promising
supplement for ex-vivo cell expansion [25,26] or as a PRP-gel
delivery vehicle for cells during transplantation [27,28]. Several
studies have suggested that PRP could be used as a supplement for
ex-vivo expansion of mesenchymal stem cells from bone marrow
[25,29,30] and adipose tissues [31]; however, no studies have been
conducted on the effects PRP has on muscle derived progenitor
cells. In the current study, we hypothesized that PRP could be a
promising candidate for the ex vivo expansion of hMDPCs and we
investigated the effect that PRP had on the proliferation and multi-
lineage differentiation capacities of the hMDPCs in vitro. We also
investigated the efficiency of PRP-expanded hMDPCs for
regenerating injured muscle in vivo.
Materials and Methods
Isolation and Cultivation of hMDPCs
Three populations of hMDPCs were used in this study: Pre-
plated muscle derived cells, myo-endothelial cells, and pericytes.
All procedures were approved by the institutional review board at
the University of Pittsburgh. Written informed consent was
obtained from all subjects. Human pre-plated muscle derived
cells (pre-plated MDPCs) were isolated by the pre-plate technique
[32,33,34,35] from three donors. Briefly, post-mortem skeletal
muscle biopsies (1 to 2 g) were obtained from the National Disease
Research Interchange (NDRI) from three male human subjects
(50–70 years old) with no known musculoskeletal diseases. The
tissue was finely minced and then serially digested with 0.2%
collagenase, 0.25% dispase, and 0.1% trypsin, for one hour each.
The digested tissue was then suspended in Dulbecco’s Modified
Eagle’s Medium (DMEM, GIBCO) supplemented with 20% fetal
bovine serum (FBS, GIBCO), 1% penicillin/streptomycin (PS,
GIBCO), and mechanically dissociated by serially passaging the
suspended tissue through 18-, 21-, and 23-gauge needles. The
resultant cell suspension was then placed in a collagen-coated flask
(0.1 g/L collagen type I, Sigma) (preplate (pp) 1). After one hour,
non-adherent cells were transferred to a fresh collagen-coated flask
(pp 2), and then 24 hours later, those in the second preplate were
transferred to another fresh collagen-coated flask (pp 3). This
procedure was repeated until pp6 was obtained. The pp6 cells
were then expanded and used for this study. Myo-endothelial cells
and pericytes were obtained from three donor muscle biopsies
which were isolated via FACS as previously described [12,16].
Briefly, fresh muscle tissue was cut into small pieces in DMEM
containing 20% FBS, 1% PS, and then enzymatically dissociated
with collagenases type I and II (1 mg/ml, Sigma). Cells were
passed through a 70 mm cell strainer, centrifuged, and re-
suspended in erythrocyte lysis buffer and incubated for 15 min
at RT. The cells were then incubated with a combination of the
following directly conjugated mouse anti-human antibodies: anti-
CD34-PE (DAKO, 1:100), anti-CD45-APC-Cy7 (Santa Cruz
Biotechnologies, 1:200), anti-CD56-PE-Cy7 (Serotec, 1:100), anti-
CD146-FITC (Serotec, 1:100), and anti-CD144-PE (BECKMAN,
1:200) for 15 min in the dark. Myo-endothelial cells (CD452,
CD56+, CD144+, and CD34+) and pericytes (CD452, CD562,
CD146+, and CD342) were sorted on a FACS-Aria flow
cytometer (BD), and then cultured under standard conditions
(see preparation of supplements and media). All hMDPCs were
expanded and used between passages 5–8 for all the experiments.
Preparation of Supplements and Media
For pre-plated MDPCs and myo-endothelial cells, DMEM-high
glucose (4.5 g/l D-glucose) with L-glutamine and 110 mg/L
sodium pyruvate (DMEM-HG), and 1% PS served as the basal
media (BM). For pericytes, DMEM-HG without sodium pyruvate,
and 1% PS served as the BM. Derivations on the BM used in the
experimental methods are defined in the sections below, i.e.
concentrations of FBS and PRP-releasate supplementation and
specific media types for in vitro differentiation studies.
Thrombin-activated PRP Releasate
Human PRP releasate was prepared according to a protocol
previously described [29,31] with some modifications. Six AB-
blood-group-typed whole blood donations were used to prepare
one pool of PRP derived from freshly prepared buffy coats
(Central Blood Bank, Pittsburgh, PA, USA). All buffy coats were
pooled together and centrifuged at 3000 g for 10 min at RT. After
centrifugation, a platelet pellet formed at the bottom with the
supernatant considered to be platelet poor plasma (PPP). At least
half of the PPP was transferred to another tube; and the platelet
pellet was then re-suspended in the remainder of the PPP to form
the PRP. The concentration of the platelets within the PRP was
determined using a hemocytometer, and standardized to 26106
platelets per microliter by adding a calculated amount of PPP.
PRP was then activated with one unit per ml human thrombin
(Sigma-Aldrich). After activation, the PRP releasate was separated
from the cellular debris by centrifugation at 3000 g for 30 min,
followed by filtration through a 0.2 mm filter. The PRP releasate
was aliquoted and stored at 280 uC until usage.
Enzyme-linked Immunosorbent Assay (ELISA)
The concentrations of transforming growth factor-beta1 (TGF-
b1), platelet derived growth factor-AB (PDGF-AB), and vascular
endothelial growth factor (VEGF) within the thrombin activated
PRP releasate were measured using commercially available ELISA
kits (DB100B, human TGF-beta1 immunoassay, Quantikine,
R&D system; DHD00B, Human PDGF-AB immunoassay,
Quantikine, R&D system; DVE00, human VEGF immunoassay,
Quantikine, R&D system).
Proliferation Assays
A DNA assay was used to determine cell growth. Briefly, 26103
hMDPCs were seeded on a 48 well plate in BM and incubated
overnight. The next day, depending on the different experimental
designs, the media was changed to different conditioned media. At
days one, three, and five, after the initial media change, the cell
lysates were prepared by the addition of 200 ml 0.1% Triton X-
100 (Sigma-Aldrich), followed by three freeze-thaw cycles. A 50 ml
aliquot of the cell lysate was used to determine double-stranded
DNA (dsDNA) content, which was measured using a Quant-iT
dsDNA high-sensitivity assay kit (Invitrogen, USA).
Long-term proliferation kinetics were tested as described
previously [29,36]. Cells were counted and passaged at a
confluence of 70–80% up to eight passages. At each passage, the
population doubling (PD) rate was determined using the formula
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x= [log10(Nh)-log10(N1)]/log10(2), where N1 is the plated cell
number and Nh is the cell number at harvest. The PD of each
passage was calculated and added to the PD of the previous
passages to generate the cumulative population doubling rate
(CPD).
Neutralization Assay
26103 hMDPCs were seeded onto a 48 well plate in BM.
Twenty-four hours later, the media were changed to different
neutralization-antibody-conditioned media, which were prepared
by adding the following neutralizing antibodies (Abs) to the culture
media supplemented with 10% PRP, and gently agitated at 4uC
for 1 h: neutralization Abs against VEGF (AF-293-NA, neutral-
izing the biological activity of VEGF165 and VEGF121; R&D
System), PDGF (AB-20-NA, neutralizing the biological activity of
natural human PDGF including PDGF-AB, BB, & AA; R&D
Systems), or TGF-b1 (TB21; neutralizing the biological activity of
human TGF-b1; Abcam); and low endotoxin isotype control Abs
(0109-14, goat IgG, SouthernBiotech; 011-001-297, rabbit IgG,
Rockland; 400124, mouse IgG, Biolegend) were also added as
controls. The effects that the neutralized PRP had on the growth
of the hMDPCs were determined using the DNA assay described
in the Proliferation Assay section.
Reverse-transcription PCR
Cellular RNA of hMDPCs was extracted using an RNeasy Mini
Kit (Qiagen). Aliquots of 1 mg total RNA were hybridized with
random primers and converted into cDNA using a SuperScript
First-Stand Synthesis System (Invitrogen). The expressions of
different gene markers were analyzed by semi-quantitative RT-
PCR. RT-PCR products were analyzed on an agarose gel and
visualized with ethidium bromide. Gel pictures were acquired
using a Gel Doc 1000 (Biorad Laboratories, USA) and the
densitometry analysis was performed with Molecular Analyst 2.1.2
(Biorad). The gene signals were normalized to b–actin. Oligonu-
cleotide primers specific to the individual markers included in this
study are presented in Table 1.
Flow Cytometry Analysis
Flow cytometry was performed on populations of hMDPCs that
were expanded in FBS (20%) or PRP (20%) supplemented media
for up to three weeks. The cells were first incubated with Abs
against the appropriate cell surface markers for 30 min in the dark.
The cells were then fixed with 0.4% paraformaldehyde, and
permeabilized with 0.1% Triton X-100 for 30 min. After three
washes with PBS, the cells were incubated with Abs against the
appropriate intracellular markers for 30 min, and fixed again with
0.4% paraformaldehyde. The following mouse anti-human
antibodies were used: CD146-FITC (Serotec), CD144-PE(BECK-
MAN), CD56-PE-Cy7(Serotec), CD34-APC (BD Pharmingen),
CD45-APC-CY7 (BD Pharmingen), CD105-PE (Invitrogen),
CD90-APC (BD Pharmingen), CD44-PE (Invitrogen), Nanog-
Alexa Fluor 647 (BD Pharmingen), Oct3/4-PerCP-Cy5.5 (BD
Pharmingen), Sox-2-V450 (BD Horizon), and HLA-DR-Brilliant
Violet 570 (BioLegend). Labeled cells were acquired and analyzed
using a FACScan flow cytometer running CellQuest software
(Becton Dickinson). Comparative analysis was performed with
FlowJo Version 7.6 (Tree Star, Inc., Ashland, OR, USA).
In vitro Differentiation Assays
For osteogenic differentiation, micromasses of 2.56105 cells
were formed by centrifugation at 400 g for 5 min and kept for 3
weeks in osteogenic media (DMEM containing 10% FBS, 100 nM
dexamethasone, 10 mM b-glycerophosphate, and 0.05 mM L-
ascorbic acid-2-phosphate). At weeks one, two, and three, cell
pellets were examined with a MicroCT scanner (VivaCT 40,
Scanco, Switzerland) and the mineralized bone volumes (BV) were
documented and compared among the groups.
For chondrogenic differentiation, micromasses of 2.56105 cells
were formed and kept for four weeks in DMEM, 100 nM
dexamethasone, 0.05 mM L-ascorbic acid-2-phosphate, 1% ITS
(insulin 25 mg/ml, transferrin 25 mg/ml, and sodium selenite
25 mg/ml), 0.35 nM proline, and 10 ng/ml recombinant human
TGF-b3 (Lonza). Cell pellets were collected after four weeks, and
histology and biochemical analyses were performed. For histology,
randomly selected pellets (n = 2 per data point) were fixed in 4%
paraformaldehyde, CMC (NEG50, Richard-Allan Scientific)
embedded, and frozen in liquid nitrogen; 5 mm sections were cut
using a cryostat (HM505E, MICROM, USA). Consecutive
sections were stained with alcian blue. For biochemical analyses,
randomly selected pellets (n = 3 per data point) were digested for
6 h at 60uC with 125 mg/ml papain in PBE buffer (100 mM
phosphate, 10 mM EDTA, PH 6.5) containing 10 mM cysteine,
by using 100 ml of enzyme per sample. Glycosaminoglycan (GAG)
content was measured using dimethylmethylene blue dye and a
spectrophotometer (Infinite M200, TECAN, NC, USA). Bovine
chondroitin sulfate was used as a standard.
For myogenic differentiation, 26104 cells were seeded onto a 24
well plate and cultured for ten days in fusion media (BM with 2%
FBS) which induces myogenic fusion of the cells into elongated,
multinucleated myotubes. At the end of culture, the cells were
fixed with cold methanol. After blocking with donkey serum,
mouse anti-human-fast myosin heavy chain (f-MHC) (m4276,
Sigma, 1:250) was added and incubated overnight at 4uC. After
washing with PBS, donkey-anti-mouse 594 (A21203, Invitrogen,
1:500) was added for two hours at RT. The nuclei were labeled
with 49, 6-diamidino-2-phenylindole (DAPI). Five fields in each
well were randomly chosen for analysis, and three replicate
experiments were performed. The percentage of fast-MHC-
expressing nuclei/total nuclei were documented and compared
among groups.
In vivo Transplantation of hMDPCs
Six to eight week old mdx-SCID mice (Jackson Laboratories,
USA) were used in this study. All experiments were carried out in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Animal Research and
Care Committee of University of Pittsburgh. All surgery was
performed under isoflurane anesthesia, and all efforts (subcutane-
ous injections of 1 mg/kg ketarolac, once daily for three days post-
op) were made to minimize suffering. hMDPCs were expanded in
PRP (20%) supplemented or FBS (20%) supplemented media for
three weeks. 16105 cells were re-suspended in 20 ml PBS and
transplanted intramuscularly in a single injection into the mdx-
SCID’s gastrocnemius muscles that had been injured one day
earlier by intramuscular injection of 20 ml cardiotoxin (0.15 mg/ml,
CTX, Molecular Probes). Animals were sacrificed 28 days after
injection and treated muscles were frozen as described previously.
Human Major histocompatibility complex (MHC) class I staining
was performed on acetone-fixed, 5% donkey serum-blocked
sections using a rabbit anti-human MHC-class-I antibody (1:600
dilution, ab52922, Abcam) and mouse anti-human mitochondria
(1:100 dilution, MAB1273, Millipore) to detect human cell-derived
myofibers. Sections were then washed in PBS and incubated with
an Alexa Fluor 594 labeled donkey-anti-rabbit IgG antibody
(A21207, Invitrogen) and Alexa Fluor 488 donkey-anti-mouse IgG
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antibody (A21202, Invitrogen). Nuclei were stained with DAPI.
Sections containing the highest number of fibers expressing human
MHC-class-I positive myofibers were imaged using fluorescence
photomicroscopy (Nikon Eclipse E800, Japan). Consecutive
sections were stained with H&E, and the images were taken in
the same area. The number of human MHC-class-I positive fibers
per section were manually counted and reported as the number of
hMHC-I positive fibers/16105 injected cells.
Statistical Analysis
All experiments were repeated at least three times, and statistical
tests were performed using SPSS 16.0 (SPSS, Inc., Chicago, IL,
USA). Data were represented as the mean 6 standard deviation
(SD). Data were tested for normality and equal variance before
analysis. Statistical differences were calculated using analysis of
variance (ANOVA; or ANOVA on ranks if equal variance testing
failed). Differences were considered significant at P,0.05.
Results
PRP Promotes the Proliferation of hMDPCs
The concentration of platelets in the pooled PRP was
standardized to 26106 platelets per ml (see methods section).
The concentrations of TGF-b1, PDGF-AB, and VEGF within the
PRP releasate were 485.25638.12 ng/ml, 297.4641.26 ng/ml,
and 648.73679.45 pg/ml respectively.
The effect that PRP had on the proliferation of the hMDPCs in
the presence of FBS was first tested. PRP (1% and 10% vol/vol)
was added to the proliferation media (BM, with 20% FBS)
inducing a significant increase in DNA content in all populations
of hMDPCs in a dose-dependent manner from day three to day
five compared to the control groups (Fig. 1A). In order to test if
PRP alone without FBS would be sufficient to support hMDPCs
proliferation, the DNA content of the hMDPCs cultured in the
PRP-only supplemented media (BM with 10% or 20% PRP
without FBS) was compared to the cells cultured with standard
proliferation media (BM with 20% FBS). PRP alone induced
proliferation of the hMDPCs in the absence of FBS in a dose
dependent manner (Fig. 1B). 20% PRP significantly increased the
proliferation of hMDPCs compared to the 10% PRP supplement-
ed media. 10% PRP alone induced-proliferation at a comparable
rate to that achieved with 20% FBS; a PRP concentration of 20%
increased the proliferation rate of the cells by day five above that
of using 20% FBS to 38.2%, 29.5%, and 76.1% in the pre-plated
MDPCs, myo-endothelial cells, and pericytes, respectively.
Cumulative population doubling rates (CPD) were calculated to
compare the effects of the different supplements (20% FBS or 20%
PRP) on the long-term expansion of the hMDPCs. CPD was
significantly higher when hMDPCs were cultured in PRP than in
the FBS up to passage 8 (Fig. 2).
PDGF Plays a Key Role in the Mitogenic/Proliferative
Effects of PRP
In order to test which growth factor(s) within PRP may be
responsible for promoting the proliferation of hMDPCs; three
major growth factor components of PRP were neutralized
separately with the addition of neutralization antibodies. The
effects that the neutralized PRPs had on the proliferation of
hMDPCs were then compared to un-neutralized PRP. Anti-
PDGF antibody inhibited the mitogenic/proliferative effects of
PRP in all the hMDPC cultures in a dose-dependent manner
(Fig. 3, anti-PDGF). For example, in the pericyte cultures, the
addition of 10 mg/ml anti-PDGF antibody resulted in a significant
decrease in DNA content when compared to the PRP control. A
higher concentration of anti-PDGF antibody (50 mg/ml) reduced
proliferation of the cells by 56% compared with the un-neutralized
PRP treated cells. Increasing the concentration of the anti-PDGF
antibody to 100 mg/ml did not further decrease the proliferation
of the hMDPCs when compared with the 50 mg/ml group, and
did not completely block the proliferative activity of the cells to the
Table 1. List of primer sequences for the tested genes.
Genes Accession No. Forward Reverse b.p.
Nanog NM-024865 CAGCCCCGATTCTTTCCACCAGTCCC CGGAAGATTCCCAGTCGGGTTCACC 390
OCT4 NM_001159542 GTGTTCAGCCAAAAGACCATCT GGCCTGCATGAGGGTTTCT 156
Sox-2 NM-003106 GGGAAATGGGAGGGGTGCAAAAGAGG TTGCGTGAGTGTGGATGGGATTGGTG 150
CD105 U37439 AGCCCCACAAGTCTTGCAG GCTAGTGGTATATGTCACCTCGC 84
CD73 NM_002526 GGCTCCTCTCAATCATGCCG CCAGAACATTTCATCCGTGTGT 102
CD90 NM_006288 TCGCTCTCCTGCTAACAGTCT CTCGTACTGGATGGGTGAACT 134
CD44 L05424 CCTGGGATTGGTTTTCATGGT CCAGCCTGCTGAGATGGTATTT 107
PAX2 NM_153427 GCCGAGGACCCGTCTAAGA TGCTGGCTGGTAAAGTGAGTC 62
BMPR-1A NM_004329 TCAGACTCCGACCAGAAAAAGT TGGCAAAGCAATGTCCATTAGTT 145
BMPR-1B NM_001203 ATTTGCAGCACAGACGGATATT GACACTGAAAATCTGAGCCTTCT 109
BMPR-2 NM_001204 CGGCTGCTTCGCAGAATCA AGGTGCTACCTTTCGAGCATA 126
ALDH NM_000689 GCACGCCAGACTTACCTGTC CCTCCTCAGTTGCAGGATTAAAG 129
RUNX2 NM_004348 TCCTATGACCAGTCTTACCCCT GGCTCTTCTTACTGAGAGTGGAA 190
ALP NM_001127501 AAGGACGCTGGGAAATCTGTG GTGGCATGGTTCACTCTCGT 56
SOX9 NM_000346 GCCAGGTGCTCAAAGGCTA TCTCGTTCAGAAGTCTCCAGAG 213
Aggrecan NM_013227 AGGAGACAGAGGGACACGTC TCCACTGGTAGTCTTGGGCAT 249
CD56 NM_000615 ACATCACCTGCTACTTCCTGA CTTGGACTCATCTTTCGAGAAGG 137
Desmin NM_001927 AACCAGGAGTTTCTGACCACG TTGAGCCGGTTCACTTCGG 137
doi:10.1371/journal.pone.0064923.t001
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levels obtained with serum-free media (Control). There were no
significant changes in proliferation in any of the hMDPC groups
treated with anti-TGF-b1 and anti-VEGF neutralizing antibodies
(Fig. 3, anti-TGF-b1 and anti-VEGF); and no significant
changes in proliferation were noticed when adding the isotype
control Abs to the PRP supplemented hMDPC cultures (Fig. S1).
PRP Expanded hMDPCs Maintained a Stem Cell Marker
Expression Profile
To determine the influence that PRP supplementation had on
the stem cell marker expression profile, we performed RT-PCR
(Tab. 2) and flow cytometry analyses (Tab. 3) on long-term
expanded hMDPCs. The hMDPCs were expanded initially for 5–
8 passages in 20% FBS. The culture media was then either
switched to media supplemented with 20% PRP or the cells
continued to be cultured in 20% FBS. After three weeks of
additional culturing, the expression profiles of the chosen markers
outlined in Tables 2 and 3 were compared between the two groups
and to the cells prior to their additional three weeks of expansion
(control, 5–8 passages post-isolation).
Three groups of genes were tested via RT PCR including: 1)
Markers for mesenchymal stem cells [37,38]: CD105 (also known
as endoglin), CD73 (also known as 59 nucleotidase), CD90 (also
known as Thy-1), CD44, PAX2, Bone morphogenetic protein
receptors (BMPRs, including BMPR1A, 1B and 2), and aldehyde
dehydrogenase (ALDH); 2) Transcription factors that play a key
role in controlling stemness [37,38]: Nanog, Oct4, and Sox-2; 3)
Markers that are related to lineage specific differentiation: Runt-
related transcription factor 2 (RUNX2), alkaline phosphatase
Figure 1. Influence of PRP on the proliferation of hMDPCs. A: Influence of PRP on the proliferation of hMDPCs in the presence of 20% FBS.
n = 4, *P,0.05. Data showed that PRP can promote the proliferation of hMDPCs in a dose-dependent manner. B: Influence of PRP on the proliferation
of hMDPCs in the absence of FBS. n = 4, *P,0.05. Data showed that PRP alone can promote the proliferation of hMDPCs in a dose-dependent manner,
and 10% PRP induced comparable effect as the 20% FBS did on the proliferation of the hMDPCs.
doi:10.1371/journal.pone.0064923.g001
Figure 2. Influence of PRP on the long-term proliferation of hMDPCs. hMDPCs were cultured in 20% PRP (PRP group). The mean cumulative
population doubling rate (CPD) was compared among the cells cultured in 20% FBS (FBS group) until passage 8. n = 3, *P,0.05 compared to FBS
group. Data showed that CPD was significantly higher when hMDPCs were cultured in PRP rather than FBS.
doi:10.1371/journal.pone.0064923.g002
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(ALP), SOX9, aggrecan, CD56 (also known as neural cell
adhesion molecule, NCAM), and desmin.
After expansion in the PRP supplemented media, the mRNA
expression levels of the preplated hMDSCs were significantly
elevated in 6 of 9 of the mesenchymal stem cell (MSC) marker
genes analyzed compared to both the low passage control cells and
the FBS long term expanded cells (Tab. 2). MSC marker gene
mRNA levels in the myo-endothelial cells were also significantly
higher in 3 of 9 genes analyzed compared to both the low passage
control cells and the FBS long term expanded cells (Tab. 2). Only
1 of 9 of the genes was significantly elevated in the PRP cultured
pericytes compared to both the low passage control cells and the
FBS long term expanded cells (Tab. 2).
Nanog, OCT4, and SOX2 mRNA levels were significantly
elevated in the PRP supplemented preplate hMDPCs, myo-
endothelial cells, and pericytes compared to the FBS supplement-
ed cultures in 2 of 3 (Nanog and Sox-2), 3 of 3, and 2 of 3 (Oct4
and Sox-2) of the genes analyzed, respectively (Tab. 2). The PRP
supplemented cells had significantly elevated gene expression
levels in 1 of 3 (Sox-2), 3 of 3, and 0 of 3 (preplate hMDPCs, myo-
endothelial and pericytes, respectively) genes, compared to the
early passage control cells (Tab. 2).
The PRP supplemented populations of cells showed no
significant increase in lineage specific mRNA expressions com-
pared to the early passage control cells, except for the pericytes
which exhibited an increase in Sox-9 expression. The PRP
supplemented cultures, however, did show a significant decrease in
the expression of certain markers compared to both the early
passage control cells and the long term FBS supplemented cultures
(Tab. 2). The real-time RT-PCR data on one population of each
hMDPCs showed similar result (Tab. S1).
The marker profiles of the hMDPCs after PRP or FBS
expansion were further analyzed by flow cytometry (Tab. 3).
The cell surface markers used to isolate myoendothelial cells and
pericytes (CD146, CD144, CD56, CD34, and CD45) demon-
strated no significant changes in positivity after expansion in either
FBS or PRP supplemented cultures (Tab. 3). The pre-plated
hMDPCs showed a heterogeneous phenotype and highly ex-
pressed CD146 (99.25%60.21), CD144 (77.34%614.41), CD56
(86.60%621.28), but not CD34 (0.42%60.22); however, no
significant change to this marker profile was found after expansion
in either the FBS or PRP supplemented media (Tab. 3).
Mesenchymal stem cell surface markers, CD105, CD44, and
CD90, were highly expressed by all three hMDPC populations in
the early passage control cells as well as by all the expanded
Figure 3. The role of growth factors in PRP on the proliferation of hMDPCs. Neutralizing antibodies against PDGF, TGF-b1, and VEGF were
added to the media to determine the role that these growth factors played in the beneficial effect that PRP had on hMDPCs proliferation. n = 4,
*P,0.05. Data showed that PDGF within the PRP played a role in stimulating the proliferation of the hMDPCs.
doi:10.1371/journal.pone.0064923.g003
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populations supplemented with either PRP or FBS (Tab. 3), and
no significant changes in positivity were found for any of these
markers in any of the hMDPC populations. Interestingly, the
mean fluorescent intensity (MFI) of CD105 and CD90 were
significantly higher in all the PRP expanded hMDPCs compared
to the control and FBS expanded cells. For example, in the pre-
Table 2. RT-PCR analysis.
mRNA Pre-plated MDPCs Myo-endothelial cells Pericytes
Control FBS PRP Control FBS PRP Control FBS PRP
CD105 0.6760.14 0.5760.16 0.6460.10 0.7060.09 0.7160.14 0.6560.16 0.5760.06 0.5860.06 0.5260.09
CD73 0.6060.04 0.6460.04 0.7560.09*# 0.7360.15 0.7060.11 0.6760.13 0.8560.07 0.6060.13 0.6360.10
CD90 0.5760.04 0.6360.09 0.7660.11*# 0.7460.14 0.6960.08 0.7160.16 0.6360.08 0.5460.10 0.5460.09
CD44 0.3660.05 0.3860.09 0.2860.19 0.4360.07 0.4760.11 0.5760.06*# 0.4060.09 0.4360.11 0.3760.08
PAX-2 0.5660.10 0.3660.09 0.4160.13 0.3860.08 0.4260.10 0.4060.09 0.3260.15 0.3560.10 0.4360.16
BMPR-1A 0.5760.05 0.5960.08 0.4260.03*# 0.3960.06 0.4160.09 0.4060.09 0.3560.11 0.3960.09 0.3460.11
BMPR-1B 0.4660.10 0.3960.09 0.5960.07*# 0.3860.07 0.3260.11 0.4660.05*# 0.3060.03 0.3460.06 0.4560.04*#
BMPR-2 0.2460.06 0.2860.09 0.3460.03*# 0.3060.05 0.2860.03 0.3760.05*# 0.2160.09 0.286011 0.2460.08
ALDH 0.2560.04 1.1060.09* 0.9960.08* 0.8960.11 0.8760.11 0.8960.09 N/A N/A N/A
Nanog 0.3760.09 N/A* 0.3260.14# 0.2860.03 0.3160.11 0.4360.08*# 0.1360.06 0.1960.06 0.1960.03
OCT-4 1.6960.17 1.2560.12* 1.7160.08# 1.4360.31 0.1360.02* 0.2860.05*# 0.3660.10 0.1360.03* 0.3360.06#
SOX-2 0.2760.06 N/A* 0.3960.07*# 0.3460.05 0.3260.11 0.4960.03*# 0.2060.12 N/A* 0.0560.00#
RUNX2 0.9960.16 1.0160.25 0.9060.22 1.2560.09 1.1360.19 1.2060.12 1.0360.06 0.9860.11 1.1260.21
ALP 0.1560.04 0.1960.04 0.1860.08 0.1960.09 0.1760.10 0.2160.11 0.1760.06 0.1560.08 0.1360.05
SOX9 0.2460.08 0.2660.07 0.3160.11 1.2060.07 1.2560.12 1.1660.16 0.2160.07 0.2660.05 0.3860.09*#
Aggrecan 0.0960.01 0.1960.06* N/A*# 0.1860.03 0.2060.06 0.0360.01*# 0.1760.02 0.2760.03* 0.1360.05#
CD56 0.3660.03 0.5060.09* 0.3860.04# 0.4160.08 0.3960.12 0.4560.09 N/A N/A N/A
Desmin 0.2660.02 0.3260.04* 0.1060.04*# 0.3860.02 0.4560.02* 0.3460.03# N/A N/A N/A
hMDPCs were expanded with FBS or PRP for 3 weeks. The controls were hMDPCs cultured at day0. Data shown are means 6 SD.
n = 3,
*P,0.05 compare to control,
#P,0.05 compare to FBS group.
N/A means the expression level was not detectable.
doi:10.1371/journal.pone.0064923.t002
Table 3. Flow cytometry analysis.
Pre-plated MDPCs Myo-endothelial cells Pericytes
Control FBS PRP Control FBS PRP Control FBS PRP
CD146 99.2560.21 98.9560.30 90.4365.35 99.6360.05 99.7860.10 96.4060.75 98.6561.17 99.1060.22 94.3061.73
CD144 77.34614.41 91.2766.55 75.24624.05 94.3065.75 97.4562.90 98.5860.71 2.1062.40 1.5160.22 0.3360.23
CD56 86.60621.28 75.58610.82 71.5762.31* 91.4364.53 91.4863.07 92.3365.89 3.7461.54 4.5661.33 7.6061.55
CD34 0.4260.22 0.3060.03 0.1460.16 93.2264.50 98.5161.83 92.4963.24 0.3960.55 0.3660.46 0.1460.10
CD45 1.8860.77 3.7762.13 3.7964.65 0.9960.14 1.1160.25 1.8160.60 0.9660.65 4.6763.32 4.7263.37
CD105 97.4063.47 98.5061.85 95.5364.35 99.4560.07 99.1560.64 99.4060.57 98.9761.45 98.3362.46 98.0763.09
CD44 98.8061.30 93.9764.50 91.8068.25 99.0361.33 98.3362.38 99.6660.21 98.6061.59 98.4062.51 99.5360.55
CD90 92.9763.09 94.2064.15 99.3760.51 97.6362.14 99.4360.32 97.4063.47 60.7064.13 99.4760.40* 99.6060.30*
HLA-DR 2.5260.66 1.7060.52 3.4463.14 0.3560.05 0.7460.14 0.4360.05 0.3560.07 1.8660.31 0.4960.11
OCT4 14.6764.98 11.7666.99 34.3961.97*# 20.92765.65 13.7062.70 57.8063.20*# 61.7666.84 24.8566.75* 52.3466.94*#
Nanog 68.8063.25 44.10610.32* 52.8566.44 30.8064.67 32.1569.55 57.9566.43*# 4.5165.79 40.4565.73* 33.70611.60*
SOX2 52.0069.42 32.4362.42* 68.5062.86# 24.1065.27 28.0368.15 33.6765.00* 41.3763.86 63.5365.07* 53.5766.59*#
hMDPCs were expanded with FBS or PRP for 3 weeks. The controls were hMDPCs cultured at day0; FBS group was hMDPCs cultured in FBS supplemented media; PRP
group was hMDPCs expanded in PRP supplemented media. The percentage of positively stained cells was quantified by flow cytometry. Data shown are mean 6 SD.
n = 3,
*P,0.05 compare to control,
#P,0.05 compare to FBS group.
doi:10.1371/journal.pone.0064923.t003
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plated MDPCs, the MFI of CD90 and CD105 was significantly
higher in the PRP group (CD90: Control, 29247.2565196.54;
FBS, 41329.0064032.05; PRP, 86618.0067765.70; CD105:
control, 4258.006506.17; FBS, 5729.606592.80; PRP,
9179.406625.98).The expression of Nanog, Oct4, and Sox-2
were also detected via flow cytometry in all the early passage
control populations (Tab. 3 control); after expansion, all three of
the PRP supplemented hMDPC populations yielded significantly
higher expression in at least 1 of 3 markers compared to the FBS
supplemented and low passage control populations (Tab. 3). For
example, Oct4 was expressed significantly more in all three
populations of the PRP supplemented cells, Nanog was expressed
significantly more by the myo-endothelial PRP supplemented cells
than the early passage control and the FBS supplemented long
term cultures, as was Sox-2 by the pericyte population (Tab. 3).
PRP Expanded hMDPCs Maintained their in vitro
Differentiation Capabilities
The differentiation abilities of all three hMDPC populations
were compared after three weeks in either the PRP (20%) or the
FBS (20%) supplemented media.
For osteogenesis, micro-CT scanning revealed an increase in
bone volume in all the hMDPCs cell pellets in both groups in a
time dependent manner. No significant differences were observed
between the PRP and FBS supplemented groups (Fig. 4
Osteogenesis).
For chondrogenesis, one population of myo-endothelial cells
and pericytes from one donor did not positively respond to
chondrogenic induction. All the other populations of hMDPCs
formed cartilage-like pellets after four weeks of induction. All the
pellets contained a significant amount of glycosaminoglycan
(GAG), and were positive for alcian blue staining (Fig. 4
Chondrogenesis); however, no significant differences were
observed between the PRP and FBS supplemented groups.
For myogenesis, human fast myosin heavy chain (f-MHC)
positive myotubes were formed in both groups on day ten. No
significant differences were observed in the percentages of f-MHC-
expressing nuclei/total nuclei when compared between the two
groups (Fig. 4 Myogenesis).
PRP-expanded hMDPCs Maintained their in vivo
Myogenic Potential
All three populations of PRP-expanded and FBS-expanded
hMDPCs were injected into the gastrocnemius muscles of mdx-
SCID mice damaged with cardiotoxin. The mean cumulative
population doublings rate (CPD) at the time of transplantation of
the PRP-expanded cells were 29.30 (pre-plated hMDPCs), 33.09
(myo-endothelial cells), and 31.57 (pericytes); and the CPD of FBS-
expanded cells were 18.73 (pre-plated hMDPCs), 21.84 (myo-
endothelial cells), and 17.78 (pericytes). Four weeks after cell
injection, human Major histocompatibility complex (MHC) class I
(red) and human mitochondria positive (green) myofibers could be
Figure 4. Differentiation abilities of hMDPCs were maintained after expansion with PRP. hMDPCs expanded either with PRP or FBS were
tested for their multi-lineage differentiation abilities. A. For osteogenesis, data showed the mineralized bone volume of the pellets at different time
points; for chondrogenesis, data showed GAG content of pellets; for myogenesis, data showed the percentage of f-MHC expressing nuclei per total
nuclei. B. representative data of pericytes. For osteogenesis, pictures of 3D mineralization within the pellets; for chondrogenesis, alcian blue staining
of the pellets; for myogenesis, immuno-staining of f-MHC (red) and nuclei (blue). Cells expanded in both culture conditions consistently differentiated
into osteogenic, chondrogenic, and myogenic lineages. There were no significant differences in regard to the multi-lineage differentiation ability
between the PRP-expanded and FBS-expanded hMDPCs (n = 3).
doi:10.1371/journal.pone.0064923.g004
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detected in the injured muscles (Fig. 5 A, Fig. S2 shows
secondary antibody only, control). Human MHC-class-I was
mainly expressed on the membrane and in the sarcoplasm of the
regenerated muscle fibers [39]; human mitochondria could be
detected in the injured area, both in the periphery of the human
MHC-class-II positive muscle fibers and around the transplanted
area [40]. All populations of hMDPCs that were expanded in PRP
supplemented media retained their ability to regenerate myofibers
Figure 5. In vivo myogenic potential of PRP-expanded hMDPCs. PRP- and FBS-expanded hMDPCs were injected into mdx-SCID
gastrocnemius muscles damaged with cardiotoxin. Cryo-sections were prepared 4 weeks after cell injection. A. HE staining and immuno-fluorescence
staining of human major histocompatibility complex (MHC) class-I (red), human mitochondria (green), and DAPI (blue) were performed on the slides
that contained the injection sites. Human MHC-I-positive and human mitochondria-positive myofibers were detected in the injured area. B.
Quantification of human MHC-I-positive fibers per 16105 injected cells. Data showed that all populations of hMDPCs that were expanded in PRP
supplemented media retained their ability to regenerate myofibers, and no significant differences were found between FBS and PRP expanded cells
(n = 4).
doi:10.1371/journal.pone.0064923.g005
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upon extended in vitro culture. The number of human MHC-class-
I positive myofibers was quantified and no significant differences
were found between the PRP and FBS expanded hMDPC
populations (Fig. 5 B).
Discussion
PRP is heterogeneous by nature due to the numerous variations
that exist in PRP preparation protocols including: 1) the starting
number of platelets, 2) the use of anticoagulants, 3) the inclusion of
leukocytes, and 4) the use of activators which can lead to different
biological effects imparted by the PRP [41,42,43,44,45]. The PRP
used in this study was leukocyte and platelet-rich plasma (L-PRP),
and is classified as Type 2A according to Mishra, A., et al.’s
classification system [46]. PRP from six donors were pooled and
the concentration of the platelets in the pooled PRP was adjusted
to 26106 platelets per microliter (around 10 times above the
baseline found in blood). The level of three primary growth factors
in the PRP (PDGF-AB, TGF-b1, and VEGF) [23,43] was
determined, and our results demonstrated that the pooled PRP
contained significant amounts of PDGF-AB and TGF-b1, and a
fair amount of VEGF, which is consistent with previous reports
from other groups [27,47]. Although autologously derived PRP is
preferable to avoid possible immune cross reactions, intrinsic
variations [43] such as altered platelet quantity and quality caused
by sex, age, and pre-existing patient conditions, [48,49,50] make it
difficult to control the quality of individual PRPs. Obtaining large
amounts of autologous PRP for expansion of stem cells in vitro
could also be problematic, as a result, allogeneic PRP drew our
attention and allogeneic platelet transfusion is well established in
the clinical setting [51,52]. Screened and tested allogeneic platelet
concentrates are available from blood banks in bulk, and their
quantity and quality are tested and controlled before use to
confirm their safety and effectiveness; however, a lack of well-
accepted quality control criteria for PRP exists, largely because of
the unknown mechanism of action of PRP and the complexity of
its components [23,53]. In this study, we normalized the
concentration of platelets, and the concentrations of major growth
factors in the PRP were tested; however, more specific quality
control criteria of PRP for specific applications require further
investigation.
Prior in vitro studies consistently demonstrated that PRP
enhanced the proliferation of a variety of human cell types
including MSCs derived from bone marrow
[25,29,54,55,56,57,58] and adipose tissue [31]. For the first time,
both short-term and long-term proliferation data revealed that
PRP also had a potent effect on the proliferation of hMDPCs, both
in the presence and absence of FBS. The PRP expanded hMDPCs
maintained their stem cell marker expression profile more
effectively than the FBS expanded cells. The PRP-expanded cells
also maintained their multi-lineage differentiation capacity, which
was confirmed by the cells’ ability to differentiate into osteogenic
and chondrogenic lineages in vitro and a myogenic lineage both
in vitro and in vivo. Taken together, our data suggest that PRP
could be used as a supplement for the expansion of hMDPCs in
place of FBS. To our knowledge, this is the first study to
demonstrate the efficacy and safety of PRP on the ex-vivo
expansion of hMDPCs. The use of PRP for hMDPC expansion
has the potential to reduce the cost of cell culture and increase the
safety of this cell-based protocol due to the fact that both PRP and
hMDPCs can be collected autologously or, under well-controlled
conditions, allogeneically.
It is well established that a number of markers associated with
the stemness of somatic stem cells are expressed simultaneously by
uncommitted MSCs, and their expression levels decrease once the
stem cells commit to a specific lineage [37,38]. It is critical to keep
the stable expression of those markers during their initial ex-vivo
expansion for later transplantation. In the current study, MSC
markers and stem cell transcription factors were chosen to
examine the effect of PRP-supplementation on the stem cell
phenotype of the hMDPCs. Among these markers, Nanog, Oct4,
and Sox-2 (markers for embryonic stem cells) were used to
demonstrate potential pluripotency [59,60,61,62,63]. Recent
studies demonstrated that these transcription factors are also
expressed by adult stem cells [64,65,66,67], and we found that
these transcription factors and mesenchymal stem cell markers
were indeed expressed by the hMDPCs. A more stable and
sustained expression of these markers was observed in cells that
were expanded in the PRP-supplemented media when compared
with cells that were expanded in the FBS-supplemented media.
One of the first steps in the commitment of MSCs to differentiate
into tissue specific regenerating cells is a shift in the balance of
these stem cell markers in favor of lineage specific markers. In the
current study we observed a reduction in the expression of lineage
specific markers by the PRP-expanded cells, which further
supported our hypothesis. Moreover, PRP was also shown to
have a strong mitogenic/proliferative effect on the hMDPCs,
which is additional evidence that PRP maintained the cells in a less
differentiated state. Since proliferation and differentiation have
been shown to be mutually exclusive in MSCs [68], failure to exit
the cell cycle could be responsible for preventing the hMDPCs
from entering into a differentiation phase.
In this study, we investigated three major growth factors
(PDGF, TGF-b1, and VEGF) [23,43] that could contribute to the
mitogenic/proliferative effects that PRP had on the hMDPCs.
Our data showed that neutralization of PDGF partially inhibited
the mitogenic/proliferative effects that PRP had on the hMDPCs
while neutralization of TGF-b1 and VEGF had little effect. These
findings suggest that the mitogenic effect that PRP had on the
hMDPCs is, at least in part, mediated by PDGF. It is well known
that there are more than three hundred growth factors within PRP
and that the function of PRP is multifactorial. In addition to
PDGF [69,70,71], TGF-b1 [72,73], and VEGF [74], many other
platelet-derived factors have been studied individually and have
been shown to strongly influence cellular proliferation and
differentiation; for example, insulin-like growth factor (IGF)
[75,76,77] and epidermal growth factor (EGF) [78,79]. PRP
contains high concentrations of all of these factors which probably
work synergistically. Further comprehensive studies are required
to fully understand the mechanisms behind the actions of PRP.
This study demonstrated that PRP promoted the proliferation
of hMDPCs and preserved their multi-linage differentiation
capacity during ex-vivo expansion. PDGF appears to be a key
growth factor within PRP that contributes to the mitogenic/
proliferative effects that PRP imparts on hMDPCs. We therefore
conclude that PRP could be used as an excellent supplement for
the ex-vivo expansion of hMDPCs; however, PRP’s major
limitation is its heterogeneity which requires the need for quality
testing prior to use.
Supporting Information
Figure S1 Negative controls of neutralization assay. Low
endotoxin isotype control Abs were added (goat IgG, 100 mg/ml;
rabbit IgG, 2 mg/ml; mouse IgG, 1 mg/ml) to the 10% PRP
supplemented media as controls. No significant changes in
proliferation were noticed when adding the isotype control Abs
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to the PRP supplemented hMDPC cultures compare to the PRP
groups (n = 4).
(TIF)
Figure S2 Second antibody alone controls for immuno-
staining of muscle sections. No fluorescent signals were
detected. DAPI (blue).
(TIF)
Table S1 Real-time RT-PCR analysis. Cellular RNA of
hMDPCs was extracted using an RNeasy Mini Kit (Qiagen).
Aliquots of 1 mg total RNA were hybridized with random primers
and converted into cDNA using a SuperScript First-Stand
Synthesis System (Invitrogen). Real time PCR was performed on
an iCycler iQ5 PCR machine (BioRad) using SYBR Green Master
mix (Thermo Scientific). The gene-specific primer sets were used
at a final concentration of 0.3 mM. All real time PCR assays were
performed in triplicates. Gene expression was calculated using the
relative standard curve method. Expression of the specific markers
were normalized to b-actin and then scaled according to the
control sample. This value was set to 1. Values are average of the
triplicates.
(DOCX)
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